Statement of Dr. Larry Corey on the Results of the iPrEx Study of HIV Prevention
SEATTLE, Nov. 23, 2010 /PRNewswire/ -- Congratulations to the investigators and staff who conducted iPrEx, a rigorous trial of HIV prevention by administration of daily anti-retroviral medicine to men at high risk of HIV infection. This was a well-designed and well-executed trial that has demonstrated that HIV may be prevented through this type of biomedical intervention.
Pre-exposure prophylaxis (PrEP) is an exciting addition to the "toolbox" of HIV prevention strategies. Information regarding these findings should help health care providers develop comprehensive prevention plans with those patients who identify themselves as being at high risk for HIV. The field looks forward to results from additional studies to assess the effectiveness of PrEP in other populations, learn more about people's willingness to use medication on a long-term basis, and study the safety and efficacy of PrEP administered with different regimens and/or schedules. Future studies of PrEP and other HIV prevention modalities should provide insight on how to extend the durability of prevention effects to impact the epidemic on a population basis.
This is the third positive prevention trial result in the past year, and welcome news. We are committed to the quest for a safe, effective, durable and affordable vaccine that will work around the world to prevent HIV infection. Vaccines are a key public health strategy to end viral epidemics, particularly in resource-constrained regions.
The HIV Vaccine Trials Network encourages interested people to join us in discussing the impact of the iPrEx study results on the field of HIV vaccine research. Please check www.hvtn.org or your local HIV Vaccine Trials Unit for information on how to join us.
Dr. Corey is the Principal Investigator of the HIV Vaccine Trials Network (HVTN), based at Fred Hutchinson Cancer Research Center in Seattle, Washington. HVTN, funded and supported by the National Institutes of Allergy and Infectious Diseases at the U.S. National Institutes of Health, is the largest international group conducting HIV vaccine studies in humans.
SOURCE HIV Vaccine Trials Network
Alexander, +1-206-910-3801, for HIV Vaccine Trials Network
Web Site: http://www.hvtn.org
Posted: November 2010